RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
RenovoRx today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs.